Authors
Latest:
Transitioning Sleep Schedules for School in Pediatric Patients: Carol Rosen, MDThe professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins. [WATCH TIME: 3 minutes]
Latest:
Eric Baron, DO, on the Approval of CT-132: A Digital Shift in Migraine CareBaron, a neurologist and headache specialist at Cleveland Clinic, explained the significance, clinical data, and patient potential behind CT-132, the first FDA-approved digital therapeutic for migraine prevention.
Latest:
Equity in the Media and AcademiaThere should be a holistic approach to how the systems in place affect equity: how medicine is practiced and research is conducted, the structure of academic institutions, and how media influence our perceptions of neurologic conditions.
Latest:
FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas in Adults and ChildrenThe kinase inhibitor was approved for patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Latest:
Promising Developments in Pharmaceutical Treatments for Sleep Apnea: Sanjay R. Patel, MD, MSThe director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a novel pharmacologic treatment that shows potential as an alternative to continuous positive airway pressure for sleep apnea. [WATCH TIME: 5 minutes]
Latest:
Post Hoc Analysis Highlights Brexpiprazole’s Efficacy and Tolerability in Alzheimer AgitationAs the first FDA-approved treatment for Alzheimer agitation, brexpiprazole showcased effective symptom relief with a favorable safety profile.
Latest:
Bridging Engineering and Neuroscience in the Creation of Artificial Axons for Myelination Research: Krystyn J. Van Vliet, PhD & Anna Jagielska, PhD, MScThe professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]
Latest:
Unmet Needs in Narcolepsy and Clinical PearlsNeurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
Latest:
Targeting A3AR in Trigeminal Neuropathic Pain: A Promising Approach for an Unmet Clinical NeedMarcela Romero-Reyes, DDS, PhD, FAHS, director of the Brotman Facial Pain Clinic at the University of Maryland, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain.
Latest:
Overviewing Phase 2 Data of Imlifidase in Guillain-Barré Syndrome: Elisabeth Sonesson, PhDThe vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]
Latest:
Improving Quality of Life, Digestive Health in Duchenne Muscular Dystrophy: David Brumbaugh, MDThe associate professor of pediatrics at the University of Colorado School of Medicine talked at the 2023 MDA Conference about how digestive health impacts patients with Duchene Muscular Dystrophy. [WATCH TIME: 4 minutes]
Latest:
Continuing the Vision of June Halper: What's Next for CMSCKathleen Costello discusses her new role as interim CEO of the CMSC. She has the support of Jeff Wilken, CMSC president, and Tina Trott, CMSC director.
Latest:
Efficacy of Adjunctive Therapies for Acute Ischemic Stroke Based on Phase 3 MOST Trial: Opeolu Adeoye, MD, MS; Andrew Barerrto, MD, MSThe professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]
Latest:
The Need for More Sleep Education in Medicine: Yuri Maricich, MD, MBAThe internal medicine physician and chief medical officer and head of development at Pear Therapeutics offered his perspective on the current focus that is given to sleep in clinical care and the lack of education on interventions. [WATCH TIME: 2 minutes]
Latest:
Future Plans for ALZ-801 in Homo- and Heterozygous Populations: Susan Abushakra, MDThe chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]
Latest:
Adapting to Changes in Alzheimer Disease Trials and Therapeutics: Ivana Rubino, PhD, MScThe head of Global Medical for Neuropsychiatry and Alzheimer Disease at Biogen commented on challenges with conducting effective trials for Alzheimer disease and the potential research opportunities with newly approved novel treatments. [WATCH TIME: 6 minutes]
Latest:
Significance of Recently Approved Mirdametinib for NF1-Associated Plexiform Neurofibromas: P. Leia Nghiemphu, MDThe neurooncologist from the University of California Los Angeles provided clinical insight on the impact of a new treatment option for adults and children with neurofibromatosis type 1 that are not amenable to complete surgical resection. [WATCH TIME: 2 minutes]
Latest:
COVID-19’s Effect on the BrainAs many as 1 in 3 infected with COVID-19 have longer-term neurological or mental health symptoms.
Latest:
Disease-Modifying Therapies and COVID-19 Antibody Response: Joshua Katz, MDThe chairman of the Clinical Advisory Committee of the New England Chapter of the National MS Society addressed the role DMTs play in patient response to the COVID-19 vaccine.
Latest:
Significance of Evusheld’s Effect in Multiple Sclerosis: Svetlana P. Eckert, MDThe clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]
Latest:
Realistic Views for Developing APOE-Targeted Gene Therapies for Alzheimer Disease: Yann Le Guen, PhDThe assistant director of computational biology at Stanford University discussed where the Alzheimer disease community stands on gene therapies that target APOE, and whether missense variants will play a role. [WATCH TIME: 4 minutes]
Latest:
Using Practical Training to Enhance Movement Disorder Care: Clarisse Goas MSN, APRN-CNPThe movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]
Latest:
Emerging Approaches to the Treatment of Multiple SclerosisExperts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
Latest:
Emerging Multiple Sclerosis TreatmentsFrom Standard-of-Care Injectables to Next-Generation S1P Receptor Modulators, Newer Treatments Offer Patients Options
Latest:
Shining a Light on Movement Disorders, Advocating for Awareness and Access to Care: Andréa Merriam & Larry GiffordThe chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes
Latest:
A Mother’s Journey Through Diagnosis and Acceptance of Duchenne Muscular Dystrophy: Debra MillerThe chief executive officer and founder at CureDuchenne shared her emotional journey from her son’s diagnosis of Duchenne to embracing a new path focused on advocacy, adaptation, and resilience. [WATCH TIME: 4 minutes]
Latest:
GLP-1 Analogs Showing Broad Neuroprotective Potential Across Neurological Disorders: Paul Edison, MBBS, PhD, FRCPIThe professor of neuroscience at the Imperial College London discussed the emerging role of GLP-1 analogs as neuroprotective agents with potential benefits in neurodegenerative conditions. [WATCH TIME: 4 minutes]
Latest:
The State of Biomarkers in Multiple SclerosisAs the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
Latest:
Improving Medication Management and Education of Parkinson Disease in Hospital Settings: Patricia Clark, CNPThe nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]
Latest:
AUPN Leadership Minute Episode 22: Sharing Leadership: How to Select Vice-ChairsEpisode 23 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Robert Holloway, MD, MPH, of University of Rochester School of Medicine and Dentistry. [WATCH TIME: 6 minutes]
